HighVista Strategies Boosts Edgewise Therapeutics Stake

Institutional investor increases holding in biotech firm focused on rare diseases

Mar. 16, 2026 at 11:07am

Got story updates? Submit your updates here. ›

HighVista Strategies LLC, an investment management firm, has significantly increased its stake in Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company developing treatments for rare diseases. According to a recent 13F filing, HighVista grew its position in Edgewise by 198.5% during the third quarter, now owning approximately 0.20% of the company's shares.

Why it matters

Edgewise Therapeutics is a promising biotech firm working on novel therapies for rare and severe medical conditions, particularly in the areas of kidney disorders and neuromuscular diseases. The increased investment by HighVista Strategies suggests institutional confidence in Edgewise's pipeline and future growth potential.

The details

HighVista Strategies now owns 208,101 shares of Edgewise Therapeutics, up from 69,723 shares held in the prior quarter. This represents a 198.5% increase in the firm's position. Other major investors in Edgewise include Bank of America Corp, Algert Global LLC, Creative Planning, and the California State Teachers' Retirement System.

  • HighVista Strategies increased its Edgewise Therapeutics stake during the third quarter of 2025.

The players

HighVista Strategies LLC

An investment management firm that has significantly increased its stake in Edgewise Therapeutics.

Edgewise Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing treatments for rare diseases, particularly in the areas of kidney disorders and neuromuscular diseases.

Bank of America Corp

A major institutional investor in Edgewise Therapeutics.

Algert Global LLC

An institutional investor that has increased its position in Edgewise Therapeutics.

Creative Planning

An investment firm that owns shares of Edgewise Therapeutics.

California State Teachers' Retirement System

A large pension fund that has invested in Edgewise Therapeutics.

Got photos? Submit your photos here. ›

The takeaway

The significant increase in HighVista Strategies' stake in Edgewise Therapeutics suggests growing institutional confidence in the biotech firm's potential to develop innovative treatments for rare and severe medical conditions. As Edgewise continues to advance its pipeline, investors will be closely watching the company's progress.